Argent Biopharma (AU:RGT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Argent BioPharma Ltd., a biopharmaceutical company specializing in drug discovery, has announced an upcoming shareholder vote on its potential delisting from the Australian Securities Exchange (ASX). The vote will take place on October 1, 2024, and is contingent on the approval of a category transfer on the Financial Conduct Authority’s Official List, which would require meeting certain prerequisites and the appointment of a Sponsor. The company emphasizes there is no certainty the delisting or the transfer to the London Stock Exchange’s equity shares category will occur without fulfilling these conditions.
For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.